Filtered By:
Drug: Warfarin
Education: Study

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 2155 results found since Jan 2013.

Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives
Publication date: Available online 3 May 2016 Source:Journal of Pharmacological Sciences Author(s): Toshinori Takagi, Hideaki Hara Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including antiplatelet and vasodilatation effects and protective effects on endothelial cells. Cilostazol also reportedly reduced stroke recurrence, poststroke intracranial hemorrhaging, and extracranial bleeding in a meta-analysis. Although it is known that cilostazol has the potential to suppress hemorrhagic stroke, the precise mechanisms remained unclear. Therefore, we evaluated the protective effects ...
Source: Journal of Pharmacological Sciences - June 15, 2016 Category: Drugs & Pharmacology Source Type: research

Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study
Conclusions</div>Among anticoagulant-naïve AF patients, treatment with NOACs was not associated with significantly lower risk of stroke/TE compared with VKA, but intracranial bleeding risk was significantly lower with dabigatran and apixaban.</span>
Source: European Heart Journal - October 14, 2016 Category: Cardiology Source Type: research

Factors Associated with Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with New-Onset Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists and had higher socioeconomic status. Trial Registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 4, 2017 Category: Cardiology Source Type: research

Hemorrhagic transformation of ischemic strokes: risk factors and prognostic implications (P4.291)
Conclusions:IV thrombolytic therapy, cardioembolic stroke and prior warfarin use were independent predictors of HT. PH2 was associated with increased risk of poor outcome at around 90 days and mortality at 90 days and 5 years.Disclosure: Dr. Cheung has nothing to disclose. Dr. Chan has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cheung, R., Chan, K. H., Lee, R. Tags: In-Hospital Stroke Care Source Type: research

Difference of Clinical Condition of Ischemic Stroke between Warfarin and Direct Oral Anticoagulants (P6.285)
Conclusions:Ischemic lesion size may be smaller in DOACs compared with warfarin. There is a possibility that direct thrombin inhibitor may provide better outcome compared with other anticoagulants. Larger prospective study should be conducted to confirm these findings.Disclosure: Dr. Nakase has nothing to disclose. Dr. Moroi has nothing to disclose. Dr. Ishikawa has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Nakase, T., Moroi, J., Ishikawa, T. Tags: Prevention of Cerebrovascular Disease Source Type: research

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
CONCLUSIONS: There is not enough evidence for or against NOACs or for high-intensity VKA compared to the standard VKA therapy in the secondary prevention of thrombosis in people with APS. There is some evidence of harm for high-intensity VKA regarding minor and any bleeding. The evidence was also not sufficient to show benefit or harm for VKA plus antiplatelet agent or dual antiplatelet therapy compared to a single antiplatelet drug. Future studies should be adequately powered, with proper adherence to treatment, in order to evaluate the effects of anticoagulants, antiplatelets, or both, for secondary thrombosis prevention...
Source: Cochrane Database of Systematic Reviews - October 2, 2017 Category: General Medicine Authors: Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A Tags: Cochrane Database Syst Rev Source Type: research

Comparison of Stroke- and Bleed-related Healthcare Resource Utilization and Costs among Patients with Newly Diagnosed Non-Valvular Atrial Fibrillation and Newly Treated with Dabigatran, Rivaroxaban, or Warfarin.
CONCLUSIONS: The results suggest that dabigatran patients had lower bleed-related HCRU and lower bleed-related PPPM costs than rivaroxaban patients, and lower outpatient stroke-related HCRU, higher bleed-related outpatient HCRU, and lower bleed-related PPPM costs than warfarin patients. It provides valuable stroke-related and bleed-related HCRU and costs information among commercially-insured and Medicare patients. PMID: 30251553 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Temporary oral anticoagulation after MitraClip - a strategy to lower the incidence of post-procedural stroke?
CONCLUSIONS: Temporary oral anticoagulation might be a strategy to reduce the incidence of stroke within the first 30 days after the MitraClip procedure. Bleeding events were not significantly altered due to temporary oral anticoagulation. PMID: 30650019 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - January 18, 2019 Category: Cardiology Tags: Acta Cardiol Source Type: research

Effect of Warfarin on Ischemic Stroke, Bleeding, and Mortality in Patients with Atrial Fibrillation Receiving Peritoneal Dialysis
ConclusionThere is no significant association between warfarin treatment with risks of mortality, ischemic stroke or bleeding in patients with atrial fibrillation receiving peritoneal dialysis.
Source: American Journal of Cardiovascular Drugs - April 22, 2019 Category: Cardiology Source Type: research

Augmented Intelligence Decision Tool for Stroke Prediction Combines Factors from CHA2DS2 ‐VASc and the Intermountain Risk Score for Patients with Atrial Fibrillation
ConclusionsA temporally dynamic risk score, IMRS ‐VASc was derived and validated as a predictor of stroke in AF outpatients. IMRS‐VASc requires further validation and the evaluation of its use in guiding care and treatment decisions for AF patients.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - May 21, 2019 Category: Cardiology Authors: Benjamin D. Horne, Victoria Jacobs, Heidi T. May, Kevin G. Graves, T. Jared Bunch Tags: ORIGINAL ‐ CLINICAL Source Type: research

Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation
The objective of this study was to compare the risk of stroke in atrial fibrillation (AF) with adherent use of oral anticoagulation (OAC), non-adherent use, and non-use of OAC.MethodsUsing 2013 –2016 Medicare claims data, we identified patients newly diagnosed with AF in 2014–2015 and collected prescriptions filled for OAC in the 12 months after AF diagnosis (n = 39,272). We categorized participants each day into three time-dependent exposures: adherent use (≥ 80% of the previous 30 days covered with OAC), non-adherent use (0–80% covered with OAC), and non-use (0%). We constructed Cox proportional hazards m...
Source: American Journal of Cardiovascular Drugs - September 15, 2019 Category: Cardiology Source Type: research

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
CONCLUSIONS: The evidence identified indicates that NOACs compared with standard-dose VKAs may increase the risk of stroke and do not appear to alter the risk of other outcomes (moderate-certainty evidence). Using high-dose VKA versus standard-dose VKA did not alter the risk of any thromboembolic event or major bleeding but may increase the risk of any form of bleeding (low-certainty evidence). Standard-dose VKA combined with an AP agent compared with standard-dose VKA alone may increase the risk of any thromboembolic event and does not appear to alter the risk of major bleeding or other outcomes (low-certainty evidence). ...
Source: Cochrane Database of Systematic Reviews - October 12, 2020 Category: General Medicine Authors: Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A Tags: Cochrane Database Syst Rev Source Type: research

Antiplatelet Agents and Oral Anticoagulant Use in Patients with Atrial Fibrillation and Carotid Artery Disease After First-Time Ischaemic Stroke
CONCLUSIONS: The results suggest for patients with AF and carotid artery disease after ischaemic stroke, receiving NOACs without APA is associated with a lower risk of major bleeding with no negative impact on recurrent stroke or mortality. Evidence from randomised trials is needed to confirm this finding.PMID:36692658 | DOI:10.1007/s10557-023-07433-4
Source: Atherosclerosis - January 24, 2023 Category: Cardiology Authors: Stephanie L Harrison Benjamin J R Buckley Deirdre A Lane Elnara Fazio-Eynullayeva Paula Underhill Andrew Hill David J Werring Gregory Y H Lip Source Type: research

Analyzing and predicting the risk of death in stroke patients using machine learning
ConclusionWe used several highly interpretive machine learning models to predict stroke prognosis with the highest accuracy to date and to identify heterogeneous treatment effects of warfarin and human albumin in stroke patients. Our interpretation of the model yielded a number of findings that are consistent with clinical knowledge and warrant further study and verification.
Source: Frontiers in Neurology - February 3, 2023 Category: Neurology Source Type: research